Rituximab Completed Phase 2 Trials for Multiple Myeloma and Plasma Cell Neoplasm Treatment

IndicationsStatusPurposePhase
CompletedTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT00258206Rituximab and Cyclophosphamide in Treating Patients With High Risk, Refractory, or Relapsed Multiple Myeloma
NCT00003554Rituximab in Treating Patients With Multiple Myeloma